Young breast cancer survivors can boost their chance of remaining cancer-free by inducing artificial menopause, a major Australian-led study has found.
The idea is to reduce levels of oestrogen, the female sex hormone known to fuel the re-growth of hormone-sensitive tumours, which account for about 80 per cent of breastcancers in under-50s.
Standard treatment for survivors is a drug called tamoxifen that suppresses the hormone.
However, researchers found that by adding ovarian suppression to this treatment, they were able to further reduce a patient's risk of tumour recurrence by 22 per cent over five years.
Four to five extra women out of every 100 treated would remain cancer-free under the new regimen, researchers led by Dr Prudence Francis of the Peter MacCallum Cancer Centre wrote in the New England Journal of Medicine on Friday.
Ovarian suppression was even more effective when tamoxifen was replaced with a drug called exemestane, which blocks oestrogen synthesis, they found.
"For young women, and women who still produce oestrogen after chemotherapy, this is a practice-changing study," Dr Francis told AAP.
She predicted artificial menopause would become standard practice for survivors of hormone-sensitive breast cancer aged under 35, for whom it was especially effective.
